NNMT and neoplasm: NNMT immunoreactivity was seen in 52.4%, 65.4%, 90%, and 90% of patients within the endometrial tumor, stroma adjacent to the tumor, omental metastatic tumor, and stroma adjacent to the metastatic omental tumor, respectively.